印度出现普那霉素耐药性。
Emergence of pristinamycin resistance in India.
机构信息
Department of Pharmacology and Microbiology, Moti Lal Nehru Medical College, Allahabad, Uttar Pradesh, India.
出版信息
Indian J Pharmacol. 2009 Feb;41(1):47-8. doi: 10.4103/0253-7613.48884.
Abstract
Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 mug and 25 mug, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.
摘要
奎奴普丁-达福普汀组合已被推荐为治疗多重耐药（MDR）革兰阳性球菌（GPC）的首选药物。我们报告了两例由耐甲氧西林金黄色葡萄球菌（MRSA）引起的新生儿败血症，这些病例均表现出初始体外普雷霉素耐药性。这两例的普雷霉素最低抑菌浓度（MIC）分别为 30 微克和 25 微克。应重新评估普雷霉素作为治疗 MDR GPC 感染的普遍应用。
相似文献
1
Emergence of pristinamycin resistance in India.
Indian J Pharmacol. 2009 Feb;41(1):47-8. doi: 10.4103/0253-7613.48884.
2
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
3
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Braz J Infect Dis. 2001 Feb;5(1):21-31. doi: 10.1590/s1413-86702001000100004.
4
Streptogramins for the treatment of infections caused by Gram-positive pathogens.
Expert Rev Anti Infect Ther. 2021 May;19(5):587-599. doi: 10.1080/14787210.2021.1834851. Epub 2020 Oct 26.
5
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Indian J Med Res. 2004 Dec;120(6):546-52.
6
In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
J Antimicrob Chemother. 1998 Mar;41(3):349-55. doi: 10.1093/jac/41.3.349.
7
Emergence of Staphylococcus aureus strains resistant to pristinamycin in Sfax (Tunisia).
Pathol Biol (Paris). 2012 Dec;60(6):e71-4. doi: 10.1016/j.patbio.2011.10.012. Epub 2012 Jan 20.
8
Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139.
9
A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
J Antimicrob Chemother. 1997 May;39 Suppl A:53-8. doi: 10.1093/jac/39.suppl_1.53.
10
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Drugs. 1996;51 Suppl 1:31-7. doi: 10.2165/00003495-199600511-00007.
引用本文的文献
1
Pristinamycin-antibiotic combinations against methicillin-resistant Staphylococcus aureus recovered from skin infections.
BMC Infect Dis. 2025 Sep 16;25(1):1107. doi: 10.1186/s12879-025-11433-0.
2
Antibiotics and bioactive natural products in treatment of methicillin resistant Staphylococcus aureus: A brief review.
Pharmacogn Rev. 2015 Jan-Jun;9(17):29-34. doi: 10.4103/0973-7847.156329.
3
4
Bacteriophage types of methicillin-resistant Staphylococcus aureus in a tertiary care hospital.
Australas Med J. 2013 Oct 31;6(10):496-503. doi: 10.4066/AMJ.2013.1742. eCollection 2013.
5
Quinpristin-Dalfopristin resistance among methicillin-resistant strains of staphylococci.
Indian J Pharmacol. 2010 Feb;42(1):56. doi: 10.4103/0253-7613.62403.
本文引用的文献
1
Staphylococcal resistance to streptogramins and related antibiotics.
Drug Resist Updat. 1998;1(3):169-75. doi: 10.1016/s1368-7646(98)80036-8.
2
Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals.
J Clin Microbiol. 2003 Feb;41(2):586-91. doi: 10.1128/JCM.41.2.586-591.2003.
3
In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Diagn Microbiol Infect Dis. 2002 Aug;43(4):319-21. doi: 10.1016/s0732-8893(02)00407-8.
4
Tn5406, a new staphylococcal transposon conferring resistance to streptogramin a and related compounds including dalfopristin.
Antimicrob Agents Chemother. 2002 Aug;46(8):2337-43. doi: 10.1128/AAC.46.8.2337-2343.2002.
5
Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
Antimicrob Agents Chemother. 2002 Jul;46(7):2200-7. doi: 10.1128/AAC.46.7.2200-2207.2002.
6
Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility.
Antimicrob Agents Chemother. 2001 Jan;45(1):263-6. doi: 10.1128/AAC.45.1.263-266.2001.
7
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
8
Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics.
Antimicrob Agents Chemother. 1996 Nov;40(11):2523-8. doi: 10.1128/AAC.40.11.2523.
9
Characterisation and molecular cloning of the novel macrolide-streptogramin B resistance determinant from Staphylococcus epidermidis.
J Antimicrob Chemother. 1989 Dec;24(6):851-62. doi: 10.1093/jac/24.6.851.
Zotero 插件